Fibrobody® miRNA inhibitor Conjugate

About Linxis Biopharmaceuticals

LinXis Biopharmaceuticals is pioneering a novel drug delivery platform, Fibrobodies®, to target activated myofibroblasts across multiple fibrotic diseases. The company has a diversified pipeline of Fibrobody®-Drug Conjugates (FDCs) and imaging tracers, with its lead diagnostic program expected to enter pivotal clinical studies in 2027/2028. As a private, pre-revenue company, LinXis is actively engaging in research collaborations and consortium partnerships to advance its pan-fibrosis targeting approach, positioning itself at the intersection of targeted therapeutics and precision diagnostics in a high-unmet-need market.

Therapeutic Areas